Abstract:Proteolysis targeting chimeras (PROTACs) technology has emerged as a novel therapeutic paradigm in recent years. PROTACs are heterobifunctional molecules that degrade target proteins by hijacking the ubiquitin-proteasome system. Currently, about 20-25% of all protein targets are being studied, and most works focus on their enzymatic functions. Unlike small molecules, PROTACs inhibit the whole biological function of the target protein by binding to the target protein and inducing subsequent proteasomal degradation. PROTACs compensate for limitations that transcription factors, nuclear proteins, and other scaffolding proteins are difficult to handle with traditional small-molecule inhibitors. Currently, PROTACs have successfully degraded diverse proteins, such as BTK, BRD4, AR, ER, STAT3, IRAK4, tau, etc. And ARV-110 and ARV-471 exhibited excellent efficacy in clinical II trials. However, what targets are appropriate for PROTAC technology to achieve better benefits than small-molecule inhibitors are not fully understood. And how to rationally design an efficient PROTACs and optimize it to be orally effective poses big challenges for researchers. In this review, we summarize the features of PROTAC technology, analyze the detail of general principles for designing efficient PROTACs, and discuss the typical application of PROTACs targeting different protein categories. In addition, we also introduce the progress of relevant clinical trial results of representative PROTACs and assess the challenges and limitations that PROTACs may face. Collectively, our studies provide references for further application of PROTACs.

On-demand modular assembly for expedited PROTAC development

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

A One-Pot Photocatalytic Triazole-Based Linkerology for PROTACs

A platform for the rapid synthesis of proteolysis targeting chimeras (Rapid-TAC) under miniaturized conditions

PROTACable Is an Integrative Computational Pipeline of 3-D Modeling and Deep Learning To Automate the De Novo Design of PROTACs

Chemistries of bifunctional PROTAC degraders

PROTAC-Design-Evaluator (PRODE): An Advanced Method for In-Silico PROTAC Design

High-Throughput Miniaturized Synthesis of PROTAC-Like Molecules

An overview of PROTACs: a promising drug discovery paradigm

Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

Novel Design Strategies to Enhance the Efficiency of Proteolysis Targeting Chimeras

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges

In Silico Tools in PROTACs design

From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation

Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins

PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications

PROTACs: A Novel Strategy for Cancer Drug Discovery and Development

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

PROTAC technology: From drug development to probe technology for target deconvolution

Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery